ERBB2 and breast cancer: Combination of CDK4/6i with endocrine therapy has significantly improved PFS in patients with hormone receptor (+)/HER2(−) advanced breast cancer by effectively targeting dysregulated cell cycle progression [69, 70, 71, 72].